On December 30, 2020, a patent application for a pharmaceutical composition for treating TRPV1 activation-mediated diseases was completed in the United States, bringing the total number of completed applications to three — Korea, the U.S., and PCT. Depending on registration status, the company plans to extend the patent to China, Europe, Japan, and other regions.
This patent covers the potential of TRPV1 in various pain conditions and allows for expansion into protein therapeutics, gene therapy, and other modalities. It is expected to hold value as a use patent for various pain conditions upon registration.